Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) - Wikidata - awgldk - TriplyDB

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)

http://www.wikidata.org/entity/Q28182735

about

Non-pharmacological modulation of the autonomic tone to treat heart failure Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection The human sympathetic nervous system: its relevance in hypertension and heart failure Sympathetic nervous system overactivity and its role in the development of cardiovascular disease Treatment of hypertension in obese patients.Current controversies in data monitoring for clinical trials.Chronic heart failure: contemporary diagnosis and management GRK2 Up-Regulation Creates a Positive Feedback Loop for Catecholamine Production in Chromaffin Cells.Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.The genomic architecture of sporadic heart failure Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving β-blockers: insights from the BEST trial.Beta-blocker therapy of heart failure: an update.Centrally acting antihypertensive agents: an update.Cardiac sympathetic nerve terminal function in congestive heart failure.Sympathetic control of short-term heart rate variability and its pharmacological modulation.Neurocardiology: therapeutic implications for cardiovascular disease Scavenging superoxide selectively in mouse forebrain is associated with improved cardiac function and survival following myocardial infarction.Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.Current and future G protein-coupled receptor signaling targets for heart failure therapy Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure Adrenergic nervous system in heart failure: pathophysiology and therapy.A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients-Prescription beyond Current Guidelines.Comparison in Conscious Rabbits of the Baroreceptor-Heart Rate Reflex Effects of Chronic Treatment with Rilmenidine, Moxonidine, and Clonidine.Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure from {alpha}1-Adrenergic receptor subtypes in nonfailing and failing human myocardium Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation.Adrenergic signaling polymorphisms and their impact on cardiovascular disease.Pharmacologic modulation of parasympathetic activity in heart failure.Are the pharmacology and physiology of α₂ adrenoceptors determined by α₂-heteroreceptors and autoreceptors respectively?Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel.The role of renal denervation in the treatment of heart failure.Device therapy to modulate the autonomic nervous system to treat heart failure.Treating hypertension in patients with left ventricular dysfunction: hitting the fairway and avoiding the rough.How does renal denervation lower blood pressure and when should this technique be considered for the treatment of hypertension?The sympathetic nervous system and heart failure.The baroreceptor as a therapeutic target for heart failure.Adrenergic signaling in heart failure: a balance of toxic and protective effects.

P2860

Q26822899-352F8069-FBF3-4A13-A61A-2C2AADE6058A Q27002648-DC13F2FD-61E5-4B9F-98DC-E08EC967C01A Q28264609-73A46EF0-ACAE-4310-BBCA-146269894505 Q28279754-CB7FB43F-D9DB-492E-AAE9-E6CD0B1123E5 Q30429298-828056FE-356B-49D9-A524-FF157ADE7729 Q31085612-5B09B77E-568C-4EA6-80FA-7376B3076F3E Q33620431-137FBEF1-E7A4-40D9-88B9-6FF41A5272F2 Q33631406-A5EA7DD8-BD16-4C5B-8E15-F59B8A5E9563 Q34477958-CC99BBE0-6C56-4F24-B1FF-CB6E8D268B39 Q34892203-AB910E1F-F531-4AB3-96A2-3C35E1D33E38 Q35033305-935BA611-EC20-41B9-8A9A-DA464D6715B5 Q36092158-F1F00616-0495-4DA4-8717-3C2BC184F895 Q36723828-2FDEE94D-A187-4A62-8DAD-86252C30ED9C Q36814278-F4183838-8B95-442A-8B44-3AAE2B00F22F Q36858184-4A6248BF-77B4-420D-8D7F-EF2E86452190 Q36884019-D2A58E75-1E15-4576-A9B2-BAEF7D0F89F7 Q36969356-231785EA-C0BA-4B3D-8056-2AF05BF14282 Q37086388-EDA8954B-19FB-4A84-9B21-0D9F20DD17A9 Q37113826-5954684F-83E5-4F78-AE72-EF4511C36BD6 Q37232104-0C33509D-D8A6-459B-8897-1A20BF16A79A Q37299577-1734ACA2-832C-4257-9FD5-06ABDD4C4D1F Q37314365-126944C2-CC89-4EFC-9C5D-328DBC586836 Q37349756-4AEC080F-6D9D-4153-A5DE-60044916476C Q37349967-91CEA659-7E0A-4C19-962E-15BE8ACFB4BD Q37413483-AE8D53D9-8A80-4A00-8450-8C7DF6438988 Q37427428-286122FF-6037-4F93-8E4A-762F25BF24AE Q37428321-37C7DAD4-01E4-43F4-96EE-955AA1CB2A9A Q37432103-6744180B-990F-4A36-8721-EDAFCCDD5395 Q37692816-E2E38A48-0E45-4B55-9AE4-9E78FF662DD7 Q37776088-0A72F1A1-B5C9-4ABA-9BC2-166CF69C7CCE Q37798181-958A78FF-98D1-4B03-89E5-57D72E5F8E03 Q37887038-7FFA3543-BB27-4EFC-9139-E9A1B0CF6806 Q37965868-EA5686FD-F09A-493A-A832-77CD668F522D Q37990825-A9BCEA35-CDC6-41B2-9CFE-0FF9FC1BEBC6 Q38029559-2F9C482F-12EC-4386-AEC3-A954064EA33A Q38096899-F7734F80-081C-4591-A7FE-D78CF1102F26 Q38140796-0BC7CD6A-1155-4463-93F3-AA76F88B8DBF Q38167053-EF477AA5-F5E5-4B4A-8972-331705C83019 Q38190492-39363C48-BE23-482B-8B07-AB1F0D05B949 Q38195518-54849046-1903-4A0A-AAB2-6EBC5B8279D0

P2860

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)

http://www.wikidata.org/entity/Q28182735

description

2003 nî lūn-bûn

@nan

2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@ast

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@en

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@nl

type

label

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@ast

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@en

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@nl

prefLabel

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@ast

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@en

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@nl

P1433

Q28182735-B54ADB53-4281-4122-8443-55FC99460028

P1476

Q28182735-92F24703-CE77-474E-ABDF-937C0276E795

P2093

Q28182735-2CE3CC65-0235-4ABC-86C3-9B100C2ED81F

Q28182735-3AEB7592-5EAE-4297-B808-E8B5A8D7263E

Q28182735-417F34C4-0180-434F-A5EF-CBBFEFDA197B

Q28182735-881857A7-0FE5-4ECC-9CD7-F64F4E424C50

Q28182735-E15899FA-6849-4791-8459-C1FDA666EA59

Q28182735-F2199B35-6FA3-4BA8-8CA9-FD42BF6A80F6

Q28182735-F2E21985-5F04-4B1F-92B3-5B27E55DF7EC

P2860

Q28182735-04ED58AE-41DA-4B38-9A7E-1749CEF30D1F

Q28182735-059CD19A-4ADB-4975-8124-22D1FCFA7D5D

Q28182735-0EA9904D-CB26-4EB2-9101-3664964C476F

Q28182735-33FC4981-1E2C-4148-9C73-02D3D2F1BBF0

Q28182735-529815AC-5A74-417E-9306-396B60219F7F

Q28182735-79E56E18-3E8F-4C9A-AC5C-B4F71B047AEC

Q28182735-88461476-7097-4878-8F31-1E8E8EE47989

Q28182735-A8992AB1-0AAA-405D-8FEB-95B7BC75F9AB

Q28182735-B272162E-E048-4D48-BC6B-C03725E7050B

Q28182735-B9DB577D-D35A-461E-979C-112FE286A7D2

P304

Q28182735-8B8089E3-F01A-464C-A392-7EB38D96625D

P31

Q28182735-D0113665-F5E9-4FAF-BC74-3EFEF85366EB

P3181

Q28182735-F54CEE9A-E995-4880-9763-C3A5EB6EFADA

P356

Q28182735-B280D040-9CB9-476E-9E55-1523095C6CF5

P407

Q28182735-67AD36A8-87DC-433B-A425-0AEE33C70924

P433

Q28182735-F896F330-EBBE-4ABF-9A16-B3A87B1F0936

P478

Q28182735-D5B0EE0A-3566-44D7-988A-DB5016FA607D

P50

Q28182735-0596937B-EC49-4A6A-B3B5-177F7545EBAB

P577

Q28182735-66695E23-C701-4EE4-A6AE-28656D53A311

P698

Q28182735-DD9878B6-3417-4FCF-8BC5-14C1C634C5FC

P921

Q28182735-503DD92C-3D34-4E63-BB16-C563BC191FD7

Q28182735-9CF0A2A5-B4AA-4709-BEBC-F6531AB2DBA2

P3181

P356

S1388-9842(03)00163-6

P1433

European Journal of Heart Failure

P1476

Adverse mortality effect of ce ...... ts with heart failure (MOXCON)

@en

P2093

Curtis Wiltse

http://www.w3.org/2001/XMLSchema#string

Jay N Cohn

http://www.w3.org/2001/XMLSchema#string

Jean Rouleau

http://www.w3.org/2001/XMLSchema#string

Marc A Pfeffer

http://www.w3.org/2001/XMLSchema#string

Matthias Straub

http://www.w3.org/2001/XMLSchema#string

Norman Sharpe

http://www.w3.org/2001/XMLSchema#string

Theressa J Wright

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Effect of carvedilol on survival in severe chronic heart failure.

Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade.

Relationship between plasma norepinephrine and sympathetic neural activity.

Adverse consequences of high sympathetic nervous activity in the failing human heart.

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.

P304

659-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2556878

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S1388-9842(03)00163-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14607206

http://www.w3.org/2001/XMLSchema#string

P921